T

Telix Pharmaceuticals

Develops targeted radiation diagnostics and therapies

Vice President Medical Affairs Americas

Full-TimeUpdated on 10/20/2026
No salary listed
Expert
PharmD, PhD, MD
Remote in USA
RemoteRegional travel of 50–75% is required; international travel may also be requested.
Biology & Biotech

About the job

Requirements
  • An advanced scientific, healthcare, or medical degree, such as a PharmD, PhD, or MD, is required.
  • At least 10 years of experience in biotech, pharma, or related areas is required.
  • At least 5 years in a leadership role is required.
  • Demonstrated success fostering close cross-functional partnerships and diplomacy is required.
  • Ability to travel regionally 50–75%; international travel may be requested.
  • Comprehensive knowledge of Medical Affairs activities, pivotal trials, and the medical landscape of prostate, renal, and neuro-oncology is required.
  • Experience in a pharmaceutical environment and strong knowledge of relevant compliance and regulatory environments are required.
  • A proven track record in medical strategy, product launches, lifecycle strategy, data-generation gaps, and thought-leader engagement is required.
  • Experience with package insert development and trial designs for expanded access programs and registries is required.
  • Ability to lead, inspire, and influence a US Medical Affairs team in a matrix structure through vision and strategy setting is required.
  • Demonstrated business acumen and people-management and leadership skills, including ability to manage complex technical organizations, are required.
  • Ability to execute and achieve results through leading others while leading by example is required.
  • Ability to build successful relationships and partnerships with key business partners and investigators is required.
  • Strong interpersonal and communication skills to build relationships with internal and external stakeholders are required.
  • Strong multitasking, attention to detail, and organizational skills are required.
  • Excellent written and verbal communication, organization, and cross-functional collaboration skills are required.
Responsibilities
  • Define Medical Affairs strategy and goals in collaboration with executive Americas leadership and cross-functional global matrix leadership teams.
  • Oversee Medical Affairs operations, budget, and tactical execution while maintaining excellence, policies, and procedures.
  • Advance collaborations with key opinion leaders and establish and execute strategic scientific-engagement plans for healthcare practitioners, research groups, and centers of excellence.
  • Lead Medical Affairs strategy and tactical execution across Americas assets in alignment with commercial, marketing, and corporate objectives for the clinical pipeline and commercial launches.
  • Support launches of Illuccix, Zircaix, and Pixclara through clinical mindshare, regional publication data-gap needs, end-to-end investigator-initiated trial strategy and execution, reader-training development and implementation, medical-information request follow-up, and regional standard response letters.
  • Monitor current guidelines and key publications to drive clinical-efficacy positioning, and provide competitive-intelligence training to the Medical Affairs team for consistent communication.
  • Develop and oversee communication plans for internal and external stakeholders.
  • Provide clinical strategy and support marketing-material development, sales training, and Medical Review in Veeva for internal and external stakeholders.
  • Lead scientific-engagement strategy with key opinion leaders, healthcare providers, and professional societies, and deliver medical education and scientific communication.
  • Develop metrics for key-opinion-leader engagement by guidelines, institutions, subspecialty, and region; use data-driven decisions to inform cross-functional strategies.
  • Develop and execute publication and congress strategies, including preparing speakers for podium presentations.
  • Support theranostic clinical-practice expansion through evidence generation, data-gap identification and dissemination, collaborative partnerships, opportunities, and field intelligence to inform medical and clinical strategy.
  • Identify data gaps related to payors, healthcare-provider unmet needs, guidelines, and professional societies; lead publication strategy and timelines with medical communications.
  • Develop clinical-trial recruitment strategies to accelerate milestones, work with Clinical Operations to identify site and patient-accrual gaps, and develop metrics to monitor progress.
  • Drive medical/scientific meetings and site-engagement meetings; lead advisory boards in collaboration with development needs; support investigator meetings with Clinical Operations; and integrate findings into cross-functional lifecycle-management strategies.
  • Lead investigator-initiated research strategy and matrix alignment across development, regulatory, clinical, and marketing teams.
  • Apply expert knowledge of pivotal trial designs and investigator brochures to review and inform protocol design from the Medical Affairs perspective, incorporating field developments and key-opinion-leader feedback.
  • Maintain a high-performance team through tactical execution, clear strategy, and operational excellence.
  • Set metrics for performance coaching and team performance, and conduct team meetings.
  • Ensure team subject-matter-expert training and expectations across the portfolio, literature, key trials, and competitive intelligence; develop subject-matter-expert plans, expectations, and metrics.
  • Maintain team knowledge of local pharmaceutical regulations and ensure implementation of company policies and procedures.
  • Ensure Medical Science Liaison activities and external interactions comply with company objectives, compliance policies and procedures, and legal and ethical standards.
  • Work with clinical development, clinical operations, marketing, market access, global medical communications, pharmacovigilance, and commercial stakeholders to provide Medical Affairs input to product development and launch strategies across the Americas.
Desired Qualifications
  • Expertise in prostate, renal, and neuro-oncology radiopharmaceuticals is strongly preferred.

About the company

Telix Pharmaceuticals develops and commercializes diagnostic and therapeutic products that use targeted radiation to diagnose and treat cancer and rare diseases. Its pipeline covers urologic oncology (prostate and kidney cancers), neuro-oncology (glioma), musculoskeletal oncology (sarcoma), and bone marrow conditioning. The treatments work by delivering targeted radiation to diseased tissues, enabling more precise decisions for treatment and allowing for personalized therapy. The company differentiates itself through a global, robust supply chain and a focus on integrating diagnostic and therapeutic options to address unmet medical needs, along with strong commitments to patient care, ethical practices, and environmental responsibility. Telix’s goal is to improve quality of life and outcomes for patients by providing targeted, clinically meaningful diagnostic and therapeutic solutions that support better treatment decisions and personalized care.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Melbourne, Australia

Founded

2015

Get referred to Telix Pharmaceuticals

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • FDA approved Pixclara on September 13, 2026, opening Telix's first brain-cancer imaging market.
  • H1 2026 revenue reached $477 million, up 22%, with EBITDA rising 146%.
  • BiPASS enrolled 350 patients and Telix aligned with FDA on a U.S. NDA pathway.

What critics are saying

  • Telix still depends on FDA manufacturing acceptance for Zircaix resubmission in 2026.
  • The $2.35 billion ITM deal brings dilution, debt, and integration strain through 2027.
  • Novartis, with Lutathera and Pluvicto, attacks Telix in GEP-NETs and prostate therapy.

What makes Telix Pharmaceuticals unique

  • Telix sells both diagnostics and therapies across the same radiopharmaceutical platform.
  • Illuccix and Gozellix give Telix a commercial prostate imaging franchise in 24 countries.
  • ITM adds isotope manufacturing, distribution, and lutetium-177 supply across more than 65 countries.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Annual Performance Bonus
  • Equity-Based Incentive Program
  • Paid Vacation
  • Paid Wellness Days
  • Hybrid Work Options
  • Remote Work Options

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

16%

2 year growth

1%
Yahoo Finance
Oct 19th, 2026
Telix and Ekalia team up to produce astatine-211 in the US for cancer therapy

Telix Pharmaceuticals and Ekalia, a joint venture between IBA and Framatome, will collaborate on US production of astatine-211, an alpha-emitting isotope being studied for targeted alpha therapy. They announced the deal on October 19, 2026. The first IBA alpha-beam cyclotron will be installed at Telix's RLS Radiopharmacies site in Trevose, near Philadelphia. The parties may add more RLS sites as demand grows. The deal gives Telix long-term, priority access to the isotope for its alpha therapy pipeline, including TLX102-Tx, a candidate for glioblastoma and leptomeningeal disease. It will also supply third-party academic and industry programmes. Astatine-211 is promising, but limited production capacity has held back wider use.

Yahoo Finance
Oct 18th, 2026
Three Australian growth stocks with insider backing: PDI Gold, Telix and Codan

Simply Wall St has picked three Australian growth stocks with high insider ownership: PDI Gold, Telix Pharmaceuticals, and Codan. The screen favours fast growers that can handle higher costs as US inflation keeps interest rate risks in focus. PDI Gold (market cap A$4.3 billion) runs the Kiniéro Gold Mine in Guinea. Its reliance on oxide ore could lift costs and squeeze margins once that phase ends. Telix Pharmaceuticals (A$5.3 billion) develops radiopharmaceutical imaging agents and cancer therapies. Its imaging products brought in $803.8 million (USD) in the 2025 financial year, and growth hinges on its late-stage pipeline. Codan (A$11.4 billion) makes radio communications systems and metal detectors. Rising defence spending and demand for unmanned systems are expanding its order book.

Anderson Publishing, Ltd.
Oct 14th, 2026
Telix to present 20 abstracts at EANM 2026 Congress.

Telix to present 20 abstracts at EANM 2026 Congress. October 14, 2026 · News Release Telix has announced that it will be presenting 20 company-related abstracts at the forthcoming 39th Annual Congress of the European Association of Nuclear Medicine (EANM) scheduled for October 17-21, 2026, in Vienna, Austria. Dr. David N. Cade, Chief Medical Officer of Telix, emphasized that the company's robust presence at the event showcases the extensive development of its pipeline, which includes important therapeutic studies, precision diagnostics, and advanced technologies. He noted that the inclusion of 12 abstracts in top-rated oral presentations is a significant acknowledgment of the quality and clinical relevance of Telix's research. A symposium focusing on the future of theranostics in urologic oncology is also planned. Key presentations will feature pivotal trials such as the Phase 3 IPAX BrIGHT trial of TLX101-Tx in recurrent glioblastoma, the Phase 3 LUTEON trial of TLX250-Tx in clear cell renal cell carcinoma (ccRCC), and interim results from the PTherpan-Lu trial of TLX597-Tx in metastatic androgen pathway modulation-resistant prostate cancer (mAPMR). The event will also highlight topline Phase 3 data for TLX591-Px (Illuccix) PET imaging in prostate cancer among Chinese men, as well as real-world applications of TLX250-Px (Zircaix) in ccRCC. Additionally, Telix will sponsor the EANM Sanjiv Sam Gambhir Young Investigator Award to honor the legacy of the esteemed educator. Attendees can visit booth #527 to learn more about collaboration opportunities involving Illuccix(R), the PSMA-PET imaging agent, along with contributions from Telix's theranostic pipeline and innovative medical technologies, including the SENSEI(R) miniature drop-in gamma probe and QDOSE(R) dosimetry software. Sponsored symposium details. Title: The future doesn't wait: The next era of theranostics in urologic oncology. Date & Time: 18-Oct-26, 13:15 - 14:45 Location: Hall F2, Austria Center Vienna Chair: J. Calais, Gustave Roussy, IGR and Université Paris-Saclay, Paris, France * The theranostic revolution * The evolving role of PSMA-PET in prostate cancer * Next-generation PSMA therapeutics: Overcoming today's challenges * Panel discussion * Extending prostate cancer theranostic success to broader GU diseases Selected oral presentations. * ELEGANCE: Prospective pilot study assessing imaging performance of TLX250-Px in patients with hepatocellular carcinoma, biliary tract cancer or gastro-enteropancreatic neuroendocrine neoplasms. * * Date and Time: 18-Oct-26, 08:00 - 09:30 * Presenter: Clement Bailly * HIMIKO: TLX591-Px PET/CT in hepatocellular carcinoma. * * Date and Time: 18-Oct-26, 08:00 - 09:30 * Presenter: Rachel Bardy * Exploring carbonic anhydrase IX as a diagnostic imaging target using TLX250-Px in Von Hippel-Lindau Disease. * * Date and Time: 18-Oct-26, 15:00 - 16:30 * Presenter: Fabrizia Gelardi * LUTEON: Phase 3 study assessing safety and efficacy of TLX250-Tx in advanced ccRCC. * * Date and Time: 18-Oct-26, 15:00 - 16:30 * Presenter: Ghoufrane Tlili * Building the traceability backbone for radiopharmaceutical therapy: First results from the PDIB Secondary Standards Laboratory Network. * * Date and Time: 19-Oct-26, 08:00 - 09:30 * Presenter: Steven Graves With the exception of Illuccix, all products mentioned are investigational and have not received marketing authorization in any jurisdiction. More in theranostics. October 15, 2026 October 6, 2026

Australian Associated Press
Oct 14th, 2026
Telix highlights pivotal trials in prostate, brain and renal cancers and next generation theranostics at EANM.

Telix highlights pivotal trials in prostate, brain and renal cancers and next generation theranostics at EANM. medical research October 14, 2026 MELBOURNE, Australia and INDIANAPOLIS, Oct. 14, 2026 /PRNewswire/ - Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces that 20 company-related abstracts will be presented at the 39th Annual Congress of the European Association of Nuclear Medicine (EANM) to be held in Vienna, Austria from October 17-21, 2026. Dr. David N. Cade, Telix Group Chief Medical Officer, said, "Our expansive presence at EANM reflects the breadth and maturity of Telix's pipeline, spanning pivotal therapeutic studies, precision diagnostics and next-generation technologies. The selection of 12 abstracts for top-rated oral presentations is a strong recognition of the quality and clinical relevance of this work. We look forward to continuing this discussion at our sponsored symposium on the future of theranostics in urologic oncology." Key presentations include the Phase 3 IPAX BrIGHT trial of TLX101-Tx in recurrent glioblastoma, the Phase 3 LUTEON trial of TLX250-Tx in ccRCC, and interim results from the PTherpan-Lu trial of TLX597-Tx in mAPMR prostate cancer[[1]]. Topline Phase 3 data for TLX591-Px (Illuccix) PET[[2]] imaging of prostate cancer in Chinese men will also be presented, together with real-world experience with TLX250-Px (Zircaix[[3]]) in ccRCC, and research from its targeted alpha therapy and MedTech programs. As in previous years, Telix will support the EANM Sanjiv Sam Gambhir Young Investigator Award, in memory of an extraordinary man and inspiring educator.

Yahoo Finance
Oct 12th, 2026
Three ASX growth stocks with high insider ownership: PDI Gold, Telix and Codan

Simply Wall St has named three Australian growth stocks with high insider ownership, drawn from a screen that surfaced 111 more such companies. Persistent inflation may keep interest rates up, which tends to hurt weakly funded businesses. PDI Gold (ASX:PDI) mines gold in West Africa. Its Kiniéro mine in Guinea brings in about US$156 million in revenue, against US$47 million from Nampala, and the company has a market value of about A$4.4b. Telix Pharmaceuticals (ASX:TLX) makes radiopharmaceutical diagnostics and therapies. Its Precision Medicine unit earns about $705 million and Manufacturing Solutions $277 million, with a market value near A$5.4b. Codan earns A$506 million from communications and A$362 million from metal detection. Its market capitalisation is roughly A$12.1b.